Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases.

PURPOSE To retrospectively assess possible clinical predictors of metastatic disease to the brain in patients with non-small cell lung carcinoma (NSCLC). MATERIALS AND METHODS Institutional review board approval was obtained, informed consent was waived, and data and other information were obtained prior to implementation of HIPAA. A review was performed of 264 patients (mean age, 65 years; 158 men and 106 women) with NSCLC who had undergone imaging studies of the chest and head. Hierarchical logistic regression was used to determine the predicted probability of metastatic disease to the brain as a function of patient age and sex and of size, cell type, peripheral versus central location, and lymph node stage of the primary NSCLC. RESULTS Ninety-five (36%) patients had evidence of metastatic disease to the brain. Mean diameter of the primary tumors was 4.0 cm +/- 2.2 (standard deviation). Cell types included adenocarcinoma (136 [52%] patients), undifferentiated (68 [26%] patients), and squamous (47 [18%] patients), for which metastatic disease to the brain occurred in 43%, 41%, and 13% (P = .003) of patients, respectively. The predicted probability of metastatic disease to the brain correlated positively with size of the primary tumor (P < .001), cell type (adenocarcinoma and undifferentiated vs squamous, P = .001), and lymph node stage (P < .017) but did not correlate with age, sex, or primary tumor location. For primary adenocarcinoma without lymph node spread, the predicted probabilities of metastatic disease to the brain from 2- and 6-cm primary tumors were .14 (95% confidence interval: .06, .27) and .72 (95% confidence interval: .48, .88), respectively (P < .02). CONCLUSION The probability of metastatic disease to the brain from primary NSCLC is correlated with size of the primary tumor, cell type, and intrathoracic lymph node stage.

[1]  Bronchogenic.  Clinical tumour size and prognosis in lung cancer. Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S). , 1999, The European respiratory journal.

[2]  Anne-Marie Sykes,et al.  CT screening for lung cancer: five-year prospective experience. , 2005, Radiology.

[3]  A. Carretta,et al.  Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment , 2002, Cancer.

[4]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[5]  R. Tsuchiya,et al.  Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. , 2001, The Annals of thoracic surgery.

[6]  S. Petersen,et al.  Chromosomal Imbalances in Brain Metastases of Solid Tumors , 2000, Brain pathology.

[7]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[8]  J. Cox,et al.  Adenocarcinoma of the lung: recent results from the Veterans Administration Lung Group. , 1979, The American review of respiratory disease.

[9]  B. Strauss,et al.  Bronchogenic carcinoma; a statistical analysis of two hundred ninety-six cases with necropsy as to relationships between cell types and age, sex, and metastasis. , 1957, A.M.A. archives of pathology.

[10]  P C Goodman,et al.  Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer. , 2000, Chest.

[11]  D. Harpole,et al.  Predicting the sites of metastases from lung cancer using molecular biologic markers. , 2001, The Annals of thoracic surgery.

[12]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[13]  V. Grieneisen,et al.  Gompertzian growth pattern correlated with phenotypic organization of colon carcinoma, malignant glioma and non‐small cell lung carcinoma cell lines , 2003, Cell proliferation.

[14]  James L Mulshine,et al.  Lung cancer screening. , 2005, The oncologist.

[15]  I. Fidler,et al.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.

[16]  O. Miettinen,et al.  CT screening for lung cancer: frequency and significance of part-solid and nonsolid nodules. , 2002, AJR. American journal of roentgenology.

[17]  R. V. van Klaveren,et al.  Survival after pathological stage IA nonsmall cell lung cancer: tumor size matters. , 2005, The Annals of thoracic surgery.

[18]  Y. Nishiwaki,et al.  Visceral pleural invasion is an invasive and aggressive indicator of non-small cell lung cancer. , 2005, The Journal of thoracic and cardiovascular surgery.

[19]  R L Wahl,et al.  Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT. , 1999, Radiology.

[20]  E. Miyaoka,et al.  T2 tumors larger than five centimeters in diameter can be upgraded to T3 in non-small cell lung cancer. , 2001, The Journal of thoracic and cardiovascular surgery.

[21]  R. Figlin,et al.  Intracranial recurrence of carcinoma after complete surgical resection of stage I, II, and III non-small-cell lung cancer. , 1988, The New England journal of medicine.

[22]  Edward F Patz,et al.  Estimate of lung cancer mortality from low-dose spiral computed tomography screening trials: implications for current mass screening recommendations. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Weichselbaum,et al.  Prophylactic cranial irradiation in adenocarcinoma of the lung a possible role , 1987, Cancer.

[24]  D. Libby,et al.  Tumor size predicts survival within stage IA non-small cell lung cancer. , 2003, Chest.

[25]  Y. Nishiwaki,et al.  Prognostic factors in clinical stage I non-small cell lung cancer. , 1999, The Annals of thoracic surgery.

[26]  Claudia I Henschke,et al.  Stage of lung cancer in relation to its size: part 2. Evidence. , 2005, Chest.

[27]  T. Naruke,et al.  The size of metastatic foci and lymph nodes yielding false-negative and false-positive lymph node staging with positron emission tomography in patients with lung cancer. , 2004, The Journal of thoracic and cardiovascular surgery.

[28]  C. Angeletti,et al.  Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. , 1997, Journal of the National Cancer Institute.

[29]  J. Dalphin,et al.  Multivariate analysis of factors predictive of brain metastases in localised non-small cell lung carcinoma. , 2004, Lung cancer.

[30]  Substaging of stage I--a commentary. , 2003, Lung cancer.

[31]  K. O'Byrne,et al.  Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer , 2000, British Journal of Cancer.

[32]  Michael Thomas,et al.  S100 Family Members and Trypsinogens Are Predictors of Distant Metastasis and Survival in Early-Stage Non-Small Cell Lung Cancer , 2004, Cancer Research.

[33]  G. Bepler,et al.  Screening for lung cancer. , 2000, The New England journal of medicine.

[34]  A. Cochran,et al.  Frequency and distribution of occult micrometastases in lymph nodes of patients with non-small-cell lung carcinoma. , 1993, Journal of the National Cancer Institute.